Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0866957/Generics-in-Cardiovascular-Diseases-Market-to-2018---Loss-of-Lipitor-Market-Exclusivities-and-Impending-Patent-Expirations-of-Plavix-to-Drive-Generic-Substitution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
Summary Europe Germany France Italy Spain JapanThis report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The global generics market cardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia, thrombosis and hypertension populations in the developed countries, as well as patent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan (valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in the cardiovascular therapeutics market, making it more competitive.
In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating a year on year decline of 0.9% from 2004-2010. Patent expiries of the leading antiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause the market to increase significantly from 2010 to 2018.
Scope- Analysis of the leading therapeutic segments, including pulmonary arterial hypertension, thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris.
- Analysis of the generics in cardiovascular disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the generics in cardiovascular disorders market, including market size, annual cost of treatment and treatment usage pattern.
- Key drivers and barriers that have a significant impact on the generics market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading generic companies. The key companies studied in this report are
- Key M&A activities, licensing agreements that have taken place from 2004 to 2011 in the global cardiovascular disorders market.
Reasons to buy- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Generics in Cardiovascular Diseases Market to 2018 – Introduction 123 Generics in Cardiovascular Diseases Market to 2018 - Global Market Overview 133.1 Introduction 133.1.1 Antidyslipidemics 133.1.2 Anti-Hypertensives 153.1.3 Rise in Generics in CVD Market 153.2 Revenue 163.3 Annual Cost of Therapy 183.4 Treatment Usage Patterns 193.4.1 Disease population 203.4.2 Treatment Seeking Population 203.4.3 Diagnosed Population 203.4.4 Prescription Population 204 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape 214.1 The US 214.1.1 Revenue 214.1.2 Annual Cost of Therapy 224.1.3 Treatment Usage Patterns 244.2 Top Five Countries of Europe 264.2.1 Revenue 264.2.2 Annual Cost of Therapy 274.2.3 Treatment Usage Patterns 284.3 Japan 304.3.1 Revenue 304.3.2 Annual Cost of Therapy 314.3.3 Treatment Usage Patterns 325 Generics in Cardiovascular Diseases Market to 2018- Therapeutic Landscape 345.1 Thrombosis 345.1.1 Introduction 345.1.2 Revenue 355.1.3 Annual Cost of Therapy 365.1.4 Treatment Flow Algorithm 375.1.5 Treatment Usage Pattern 385.1.6 Drivers and Restraints 405.1.7 Drivers 405.1.8 Restraints 405.2 Pulmonary Arterial Hypertension 415.2.1 Introduction 415.2.2 Revenue 435.2.3 Annual Cost of Therapy 445.2.4 Treatment Usage Patterns 465.2.5 Treatment Flow Algorithm 485.2.6 Drivers and Restraints 485.2.7 Drivers 495.2.8 Restraints 495.3 Hypertension 505.3.1 Introduction 505.3.2 Revenue 515.3.3 Annual Cost of Therapy 525.3.4 Treatment Flow Algorithm for Hypertension 535.3.5 Treatment Usage Patterns 545.3.6 Drivers and Restraints 565.3.7 Drivers 565.3.8 Restraints 565.4 Dyslipidemia Market 575.4.1 Introduction 575.4.2 Revenue 575.4.3 Annual Cost of Therapy 595.4.4 Treatment Flow Algorithm 605.4.5 Treatment Usage Patterns 615.4.6 Drivers and Restraints 625.4.7 Drivers 635.4.8 Restraints 635.5 Coronary Artery Disease 645.5.1 Introduction 645.5.2 Revenue 645.5.3 Annual Cost of Therapy 665.5.4 Treatment Usage Patterns 675.5.5 Drivers and Restraints 695.5.6 Drivers 695.5.7 Restraints Market 705.6 Angina Pectoris Market 705.6.1 Introduction 705.6.2 Revenue 715.6.3 Cost of Therapy 725.6.4 Treatment Flow Algorithm 735.6.5 Treatment Usage Patterns 745.6.6 Drivers and Restraints 755.6.7 Drivers for the Angina Pectoris Market 765.6.8 Restraints for the Angina Pectoris Market 766 Generics in Cardiovascular Diseases Market to 2018 - Product Pipeline Analysis 776.1 Introduction 776.1.1 Research and Development Pipeline – Pulmonary Arterial Hypertension 786.1.2 Research and Development Pipeline – Dyslipidemia 816.1.3 Research and Development Pipeline – Coronary Artery Disease 876.1.4 Research and Development Pipeline – Angina Pectoris 896.1.5 Research and Development Pipeline – Thrombosis 896.1.6 Research and Development Pipeline – Hypertension 927 Generics in Cardiovascular Diseases Market to 2018 - Most Promising Pipeline Molecules 997.1 Eliquis 997.1.1 Introduction 997.1.2 Mechanism of Action 997.2 RG1658 (Dalcetrapib, JTT-705, RO4607381) 997.2.1 Introduction 997.2.2 Mechanism of Action 997.2.3 Clinical Trial Management 1 997.3 MK-0524A (Cordaptive, niacin + laropiprant) 1007.3.1 Introduction 1007.3.2 Mechanism of Action 1007.3.3 Clinical Trial Management 2 1007.4 AMR101 (LAX-101, Miraxion) 1017.4.1 Introduction 1017.4.2 Mechanism of Action 1017.4.3 Clinical Trial Management 3 1018 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape 1028.1 Teva Pharma 1028.2 Sandoz 1028.3 Actavis 1028.4 Apotex 1028.5 Watson Pharmaceuticals 1038.5.1 Watson Launches First Generic Lipitor (atorvastatin) 1038.6 Mylan 1039 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations 1049.1 Merger and Acquisition Deals (2004-2011) 1049.1.1 Deals by Year 1069.1.2 M&A Deals by Region 1079.1.3 M&A Deals by Value 1089.1.4 Deal Summary of Top 10 M&A Deals by Value 1099.2 Licensing Deals 1119.2.1 Deals by Indication 1139.2.2 Deals by Geography 1149.2.3 Deals by Year 1159.2.4 Deal Summary of Top Five Licensing Deals by Value 1169.3 Co-development Deals 1179.3.1 Deals by Indication 1179.3.2 Deals by Geography 1189.3.3 Deals by Year 1199.3.4 Deal Summary of Top Five Co-development Deals by Value 12010 Generics in Cardiovascular Diseases Market to 2018 - Appendix 12210.1 Market Definitions 12210.2 Abbreviations 12210.3 Sources 12310.4 Research Methodology 12410.4.1 Coverage 12410.4.2 Secondary Research 12510.4.3 Primary Research 12510.4.4 The report consists of the following four major sections 12510.4.5 Therapeutic Landscape 12610.4.6 Forecasting Model for Therapeutic Areas 12810.4.7 Geographical Landscape 12910.4.8 Pipeline Analysis 12910.4.9 Competitive Landscape 12910.4.10 Expert Panel Validation 12910.5 Contact Us 12910.6 Disclaimer 129
List of Tables
1.1 List of TablesTable 1: Generics in Cardiovascular Diseases Market, Patent Expiries of Leading Cardiovascular Drugs, 2011 14Table 2: Generics in Cardiovascular Diseases Market, Global, Revenue ($bn), 2004–2010 17Table 3: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn), 2010–2018 17Table 4: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2004–2010 18Table 5: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2010–2018 18Table 6: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2004–2010 19Table 7: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2010–2018 20Table 8: Generics in Cardiovascular Diseases Market, The US, Revenue ($bn), 2004–2010 21Table 9: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn), 2010–2018 22Table 10: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2004–2010 22Table 11: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2010–2018 23Table 12: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2004–2010 24Table 13: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2010–2018 24Table 14: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue ($bn), 2004–2010 26Table 15: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010–2018 26Table 16: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy($), 2004–2010 27Table 17: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010–2018 27Table 18: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2004–2010 28Table 19: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2010–2018 28Table 20: Generics in Cardiovascular Diseases Market, Japan, Revenue ($bn), 2004–2010 30Table 21: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($bn), 2010–2018 30Table 22: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2004–2010 31Table 23: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2010–2018 31Table 24: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2004–2010 32Table 25: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2010–2018 32Table 26: Generics in Thrombosis Market, Global, Revenue ($m), 2004–2010 35Table 27: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2010–2018 35Table 28: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2010 37Table 29: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2010–2018 37Table 30: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2010 38Table 31: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2010–2018 38Table 32: Generics in Pulmonary Arterial Hypertension Market, Global Revenue ($m), 2004–2010 43Table 33: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m), 2010–2018 44Table 34: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010 45Table 35: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018 45Table 36: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, ('000), 2004–2010 46Table 37: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, ('000), 2010–2018 46Table 38: Generics in Hypertension Market, Global, Revenue ($bn), 2004–2010 51Table 39: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2010–2018 51Table 40: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010 52Table 41: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018 53Table 42: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–2010 54Table 43: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2010–2018 54Table 44: Generics in Dyslipidemia Market, Global, Revenue ($bn), 2004–2010 57Table 45: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2010–2018 58Table 46: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2010 59Table 47: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2010–2018 59Table 48: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–2010 61Table 49: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2010–2018 61Table 50: Generics in Coronary Artery Disease Market, Global, Revenue ($m), 2004–2010 65Table 51: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m), 2010–2018 65Table 52: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2004–2010 66Table 53: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2010–2018 66Table 54: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2004–2010 67Table 55: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2010–2018 67Table 56: Generics in Angina Pectoris Market, Global, Revenue ($m), 2004–2010 71Table 57: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($m), 2010–2018 72Table 58: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2010 72Table 59: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2010–2018 72Table 60: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2004–2010 74Table 61: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2010–2018 74Table 62: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in PAH, 2011 78Table 63: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Regulatory and Phase III Research and Development Pipeline, 2011 81Table 64: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase II Research and Development Pipeline, 2011 82Table 65: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase I Research and Development Pipeline, 2011 84Table 66: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Pre-Clinical and Discovery Research and Development Pipeline, 2011 85Table 67: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in CAD, 2011 88Table 68: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Angina Pectoris, 2011 89Table 69: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Thrombosis (%), 2011 90Table 70: Generics in Cardiovascular Diseases Market, Global, Hypertension Regulatory Filing and Phase III Research and Development Pipeline, 2011 92Table 71: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase II Research and Development Pipeline, 2011 94Table 72: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase I Research and Development Pipeline, 2011 95Table 73: Generics in Cardiovascular Diseases Market, Global, Hypertension Pre-clinical and Discovery Research and Development Pipeline, 2011 96Table 74: Generics in Cardiovascular Diseases Market, Global, M&A Deals, 2010-2011 104Table 75: Generics in Cardiovascular Diseases Market, Global, Licensing Deals, 2010–2011 111
List of Figures
1.2 List of FiguresFigure 1: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn), 2004–2018 16Figure 2: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2004–2018 18Figure 3: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2004–2018 19Figure 4: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn), 2004–2018 21Figure 5: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2004–2018 22Figure 6: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2004–2018 24Figure 7: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004–2018 26Figure 8: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy($), 2004–2018 27Figure 9: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2004–2018 28Figure 10: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($m), 2004–2018 30Figure 11: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2004–2018 31Figure 12: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2004–2018 32Figure 13: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2004–2018 35Figure 14: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2018 36Figure 15: Generics in Cardiovascular Diseases Market, Global, Thrombosis, Treatment Flow Algorithm 37Figure 16: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2018 38Figure 17: Generics in Thrombosis Market, Global, Drivers and Restraints, 2011 40Figure 18: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m), 2004–2018 43Figure 19: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018 44Figure 20: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, ('000), 2004–2018 46Figure 21: Generics in Cardiovascular Diseases Market, Global, Pulmonary Arterial Hypertension, Treatment Flow Algorithm, 2010 48Figure 22: Generics in Pulmonary Arterial Hypertension, Global, Drivers and Restraints, 2011 48Figure 23: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2004–2018 51Figure 24: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018 52Figure 25: Generics in Cardiovascular Diseases Market, Global, Hypertension, Treatment Flow Algorithm, 2011 53Figure 26: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–2018 54Figure 27: Generics in Hypertension Market, Global, Drivers and Restraints, 2010 56Figure 28: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2004–2018 57Figure 29: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2018 59Figure 30: Generics in Cardiovascular Diseases Market, Dyslipidemia, Treatment Flow Algorithm 60Figure 31: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–2018 61Figure 32: Generics in Dyslipidemia Market, Global, Drivers and Restraints, 2010 62Figure 33: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m), 2004–2018 64Figure 34: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2004–2018 66Figure 35: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2004–2018 67Figure 36: Generics in Coronary Artery Disease Market, Global, Drivers and Restraints, 2011 69Figure 37: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($bn), 2004–2018 71Figure 38: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2018 72Figure 39: Generics in Cardiovascular Diseases Market, Global, Angina Pectoris, Treatment Flow Algorithm 73Figure 40: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2004–2018 74Figure 41: Generics in Angina Pectoris Market, Global, Drivers and Restraints, 2011 75Figure 42: Generics in Cardiovascular Diseases Market, Global Product Pipeline by Indication (%), 2011 77Figure 43: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in PAH (%), 2011 78Figure 44: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia Research and Development Pipeline by Phase (%), 2011 81Figure 45: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in CAD (%), 2011 87Figure 46: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Thrombosis (%), 2011 89Figure 47: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Hypertension (%), 2011 92Figure 48: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Year, 2004–2011 106Figure 49: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Geography, 2004–2011 107Figure 50: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Value ($m), 2004–2010 108Figure 51: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Indication (%), 2004–2011 113Figure 52: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Geography (%), 2004–2011 114Figure 53: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Year, 2004–2011 115Figure 54: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Indication (%), 2004-2011 117Figure 55: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Geography (%), 2004–2010 118Figure 56: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Year, 2004-2011 119Figure 57: GBI Research Market Forecasting Model 128
Companies Mentioned
Teva PharmaSandozActavisApotexWatson PharmaceuticalsMylan
To order this report:Pathology Industry: Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article